Ruishi Technology has secured another new round of financing worth tens of millions of yuan.
This round of financing was invested by Chengdu Huaxi Jinzhi Specialized and Sophisticated New Equity Investment Partnership (Limited Partnership) (hereinafter referred to as the "Specialized and Sophisticated New Fund") managed by Huaxi Jinzhi. The existing shareholder, Sinovation Ventures, continued to increase its investment, and Kairong Capital served as the exclusive financial advisor. The funds from this round will be used for business operations such as clinical registration, sales enhancement, and brand building, as well as continuous R & D investment in products.
In June 2025, Ruishi Technology completed tens of millions of yuan in Series A2 financing, exclusively invested by Jinke Junchuang, with Kairong Capital serving as the exclusive financial advisor. (News Link: Ruishi Technology Completes Tens of Millions of Yuan in Series A2 Financing, Exclusively Invested by Jinke Junchuang, Leading the Innovation in the Myopia Prevention and Control Industry - https://mp.weixin.qq.com/s/Oh6HnN1PrLdzYmvwFrVaig)
Driven by the upgrading of the national strategy for myopia prevention and control and the development of AI technology, Ruishi Technology relies on the globally leading AI optical - eye - brain nerve regulation technology and solid clinical evidence - based medical evidence to address the core pain points of adolescent myopia prevention and control. Starting from myopia intervention, the company gradually constructs an intelligent treatment closed - loop system of "light - eye - brain" that integrates optical stimulation, nerve regulation, and AI feedback. Focusing on the visual nerve regulation technology path, the company creates a product system of "strong technology + soft standards" to achieve "multi - point breakthroughs":
1. At the hardware level: Innovatively introduce a bionic optical module;
2. At the algorithm level: Build an intelligent regulation mechanism based on AI recognition and personalized output.
This system has a high degree of adaptability and can effectively match different visual states, usage durations, and user habits.
More importantly, during the clinical verification process, this new myopia prevention and control technology path has shown better results than traditional myopia prevention and control solutions. According to the data from a multi - center study jointly participated in by authoritative professional medical institutions such as Beijing Tongren Hospital, Sichuan Huaxi Hospital, and the Eye Hospital of Wenzhou Medical University, Ruishi Technology's related products have shown a high degree of consistency and statistical significance in controlling axial length growth and delaying refractive development.
In a real - world study of nearly 200 cases over a six - month period, the average axial length growth in the experimental group was only 0.038mm, far lower than the 0.125mm in the control group, and there were also some cases of refractive improvement.
In terms of application scenarios, Ruishi Technology is committed to seamlessly integrating treatment into daily life scenarios, achieving "treating while learning; adjusting while playing" and creating a new paradigm of unconscious treatment that integrates behavior and nerves. At the same time, relying on a network covering hundreds of professional institutions and over 1000 stores, the company has initially built an integrated closed - loop system of "product - data - service", providing a solid verification foundation for the future implementation of the long - term prescription - based treatment model.
In terms of industry influence, at the 2025 International Forum on Vision Health Innovation and Development (VisionChina2025), Ruishi Technology jointly released two group standards, "Technical Specifications for Far - Image Electronic Display Terminals" and "Technical Requirements for Visual Health of Display Products - Far - Image Electronic Display Terminals", with the Eye Hospital Affiliated to Wenzhou Medical University. This not only further consolidates Ruishi Technology's leading position in industry standard setting but also represents an important leap from a technology innovator to an industry rule - maker.
Pan Dejiao, the co - founder of Ruishi Technology, said: We are grateful to the investors in this round for their continuous optimism and firm support for Ruishi Technology's "AI + visual nerve intervention" direction. As a team with the triple advantages of "underlying original technology, real - scene verification, and industry standard discourse power" in the myopia prevention and control field, the company has achieved remarkable results in commercial transformation after years of accumulation: In the first half of 2025, the revenue increased by over 100% year - on - year, and the company achieved profitability. This round of financing will be mainly invested in the registration and application for Class III medical devices and the iteration and upgrading of core products, and will deepen the implementation of the strategy of "serious medical treatment driving consumer medical treatment". The company is accelerating the breakthrough of the traditional "hardware is the product" model and comprehensively upgrading to a builder of a "vision health operating system" centered on algorithms, data, and services. This is not only to enable 170 million Chinese teenagers to have a more scientific and effective myopia prevention and control solution and enjoy a worry - free vision, but also to create continuous growth value for investors.